Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this observational study is to evaluate the efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical practice conditions in Korea. A clinical safety profile will be also evaluated.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin, Isophane

Criteria

Inclusion Criteria:

• Any patient with type 1 and type 2 diabetes who are treated with NovoMix® 30

• Patient who signed on informed consent form

Exclusion Criteria:

• Patients who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit

• Patients who were previously enrolled in this study

• Patients with a hypersensitivity to NovoMix® 30 or to any of the excipients

• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months